Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12560429rdf:typepubmed:Citationlld:pubmed
pubmed-article:12560429lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12560429lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:12560429lifeskim:mentionsumls-concept:C0443315lld:lifeskim
pubmed-article:12560429lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:12560429lifeskim:mentionsumls-concept:C0021735lld:lifeskim
pubmed-article:12560429lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:12560429lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:12560429lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:12560429pubmed:issue3lld:pubmed
pubmed-article:12560429pubmed:dateCreated2003-1-31lld:pubmed
pubmed-article:12560429pubmed:abstractTextBecause cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics. Patients andlld:pubmed
pubmed-article:12560429pubmed:languageenglld:pubmed
pubmed-article:12560429pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12560429pubmed:citationSubsetIMlld:pubmed
pubmed-article:12560429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12560429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12560429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12560429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12560429pubmed:statusMEDLINElld:pubmed
pubmed-article:12560429pubmed:monthFeblld:pubmed
pubmed-article:12560429pubmed:issn0732-183Xlld:pubmed
pubmed-article:12560429pubmed:authorpubmed-author:BrownThomas...lld:pubmed
pubmed-article:12560429pubmed:authorpubmed-author:HassanManal...lld:pubmed
pubmed-article:12560429pubmed:authorpubmed-author:CurleySteven...lld:pubmed
pubmed-article:12560429pubmed:authorpubmed-author:EllisLee MLMlld:pubmed
pubmed-article:12560429pubmed:authorpubmed-author:VautheyJ...lld:pubmed
pubmed-article:12560429pubmed:authorpubmed-author:PattYehuda...lld:pubmed
pubmed-article:12560429pubmed:authorpubmed-author:LozanoRichard...lld:pubmed
pubmed-article:12560429pubmed:issnTypePrintlld:pubmed
pubmed-article:12560429pubmed:day1lld:pubmed
pubmed-article:12560429pubmed:volume21lld:pubmed
pubmed-article:12560429pubmed:ownerNLMlld:pubmed
pubmed-article:12560429pubmed:authorsCompleteYlld:pubmed
pubmed-article:12560429pubmed:pagination421-7lld:pubmed
pubmed-article:12560429pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:meshHeadingpubmed-meshheading:12560429...lld:pubmed
pubmed-article:12560429pubmed:year2003lld:pubmed
pubmed-article:12560429pubmed:articleTitlePhase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.lld:pubmed
pubmed-article:12560429pubmed:affiliationDepartment of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. yzpatt@umm.edulld:pubmed
pubmed-article:12560429pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12560429pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12560429pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:12560429pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12560429lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12560429lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12560429lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12560429lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12560429lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12560429lld:pubmed